Can outpatient pharmacy data identify persons with undiagnosed COPD?

American Journal of Managed Care

Volumn 16, Issue 7, 2010, Pages 505-512

  Mapel, Douglas W ^a   Petersen, Hans ^b   Roberts, Melissa H ^b   Hurley, Judith S ^b,d   Frost, Floyd J ^b   Marton, Jenö P ^c  

^a LOVELACE CLINIC FOUNDATION   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d Hurley Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTITUSSIVE AGENT; MACROLIDE; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADRENERGIC ACTIVITY; ALGORITHM; ARTICLE; CASE CONTROL STUDY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PHARMACY; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; EARLY DIAGNOSIS; EMPHYSEMA; HEALTH CARE PLANNING; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MANAGED CARE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY; SMOKING; SPIROMETRY; STANDARD; AGED; AMBULATORY CARE; DIAGNOSTIC ERROR; FEMALE; MALE; MIDDLE AGED; PHARMACY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; UNITED STATES; VALIDATION STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; AMBULATORY CARE; COMMUNITY PHARMACY SERVICES; DIAGNOSTIC ERRORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW MEXICO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77955458648     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. CDC. Deaths from chronic obstructive pulmonary disease - United States, 2000-2005. MMWR. 2008;57(45):1229-1232.
2. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 suppl):121S-126S.
3. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ. 2002;51(6):1-16.
4. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000;160(11):1683-1689.
5. Coultas DB, Mapel D, Gagnon R, Lydick E. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med. 2001;164(3):372-377. (Pubitemid 32778201)
6. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272(19):1497-1505.
7. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675-679. (Pubitemid 34971849)
8. Murray RP, Connett JE, Rand CS, Pan W, Anthonisen NR. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Prev Med. 2002;35(4):314-319. (Pubitemid 35365396)
9. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233-239. (Pubitemid 40216240)
10. Anthonisen NR, Woodlrage K, Manfrede J. Use of spirometry and respiratory drugs in Manitobans over 35 years of age with obstructive lung diseases. Can Respir J. 2005;2(2):69-74.
11. US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;148(7):529-534.
12. Lin K, Watkins B, Johnson T, Rodriguez JA, Barton MB; US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventive ServicesTask Force. Ann Intern Med. 2008;148(7):535-543.
13. Qaseem A, Snow V, Shekelle P, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007;147(9):633-638.
14. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. December 2009. http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intld=2180. Accessed December 30, 2009.
15. Jansson SA, Lindberg A, Ericsson A, et al. Cost differences for COPD with and without physician-diagnosis. COPD. 2005;2(4):427-434. (Pubitemid 43879441)
16. Mapel DW, Robinson SB, Dastani HB, Shah H, Phillips AL, Lydick E. The direct medical costs of undiagnosed chronic obstructive pulmonary disease. Value Health. 2008;11(4):628-636. (Pubitemid 352032816)
17. Mapel DW, Frost FJ, Hurley JS, et al. An algorithm for the identification of undiagnosed COPD cases based on health care utilization data. J Manag Care Pharm. 2006;12(6):457-465.
18. Mapel DW, McMillan GP, Frost FJ, et al. Predicting the costs of managing patients with chronic obstructive pulmonary disease. Respir Med. 2005;99(10):1325-1333. (Pubitemid 41245321)
19. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Courtes DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med. 2000;160(17):2653-2658.
20. Sethi S, Mallia P, Johnston SL. New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. Proc Am Thorac Soc. 2009;6(6):532-534.
21. Lange P. Chronic obstructive pulmonary disease and risk of infection. Pneumonol Alergol Pol. 2009;77(3):284-288.
22. Sapey E, Stockley RA. COPD exacerbations, 2: aetiology. Thorax. 2006;61(3):250-258.
23. Rodríguez-Roisin R, Soriano JB. Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease. Proc Am Thorac Soc. 2008;5(8):842-847.
24. Halpin D. Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena. COPD. 2008;5(3):187-200.
25. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245-1257.
26. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003;21(6):1012-1016. (Pubitemid 36675619)
27. Schünemann HJ, Dom J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118(3):656-664.
28. Bang KM, Gergen PJ, Kramer R, Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993;103(2):536-540. (Pubitemid 23070759)
29. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711-715. (Pubitemid 26313070)
30. Centers for Medicare and Medicaid Services. CMS Legislative Summary. April 2004. Summary of H.R. 1 Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Public Law 108-173. Enacted December 8, 2003. Washington, DC. http://www.cms.hhs.gov/MMAUpdate/downloads/PL108-173summary.pdf. Accessed November 30, 2009.
31. Heron MP, Hoyert DL, Murphy SL, Xu JQ, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57(14):1-134.
32. Faulkner MA, Lenz TL, Stading JA. Cost-effectiveness of smoking cessation and the implications for COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(3):279-287.
33. Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence - and implications for coverage. Pharmacoeconomics. 1997;11(6):538-549.
34. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from theTORCH Study. Am J Respir Crit Care Med. 2008;178(4):332-338.
35. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest. 2007;131(3):682-689. (Pubitemid 46446857)
36. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH study. Respir Res. 2009;10:59.
37. Celli BR, MacNee W, ERS TF. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [published correction appears in Eur Respir J. 2006;27(1):242]. Eur Respir J. 2004;23(6):932-946.